TB, clinical trials, immunotherapy, TB treatment
At Immunocore, we are applying our bi-specific T cell receptor (TCR) technology platform outside of oncology to the discovery of new treatments for infectious diseases that pose a global health challenge. Immune Mobilising Monoclonal TCRs Against Viruses or Bacteria (ImmTAV®, ImmTAB®) molecules enable the immune system to recognise and kill diseased cells, in this case, virally or bacterially infected cells. Our initial target indications are HIV, chronic Hepatitis B and Tuberculosis (TB).
ImmTAB® molecules have the potential to reduce treatment timelines, improve patient outcomes and ultimately "functionally cure" infections for which no cure exists today. The development of our ImmTAB® technology is supported by The Bill & Melinda Gates Foundation.
Available at Immonocore